Scailyte
Scailyte is a clinical-stage precision medicine company that leverages artificial intelligence and single-cell analysis to develop breakthrough diagnostic and companion diagnostic solutions. Founded in 2017 as an ETH Zürich spin-off, Scailyte aims to address critical healthcare challenges by ensuring that patients receive the most effective treatments through its proprietary ScaiVision AI platform. The company has successfully analyzed over 1,000 single-cell samples and developed a pipeline of innovative products that utilize deep multimodal data insights to enhance patient outcomes in complex diseases such as cancer and autoimmune disorders.
Scailyte
Scailyte is a clinical-stage precision medicine company that leverages artificial intelligence and single-cell analysis to develop breakthrough diagnostic and companion diagnostic solutions. Founded in 2017 as an ETH Zürich spin-off, Scailyte aims to address critical healthcare challenges by ensuring that patients receive the most effective treatments through its proprietary ScaiVision AI platform. The company has successfully analyzed over 1,000 single-cell samples and developed a pipeline of innovative products that utilize deep multimodal data insights to enhance patient outcomes in complex diseases such as cancer and autoimmune disorders.